Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

Adolescent and young adult survivors of cancer face increased substance use risks due to developmental delays, limited ...